Towards a molecular therapy for glycogen storage disease type II (Pompe disease)

Molecular Medicine Today

Volumn 6, Issue 6, 2000, Pages 245-251

  Chen, Yuan Tsong ^a   Amalfitano, Andrea ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE;

ENZYME ACTIVITY; ENZYME REPLACEMENT; GENE THERAPY; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; LIVER CELL; MOLECULAR BIOLOGY; NONHUMAN; REVIEW;

ANIMALS; FORECASTING; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS;

EID: 0034212568     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(00)01694-4     Document Type: Review

References (41)

1. Hirschhorn R. Glycogen storage disease type II: acid α-glucosidase (acid maltase) deficiency. Scriver C.R.et al. The Metabolic and Molecular Basis of Inherited Disease. 1995;2443-2464 McGraw-Hill.
2. Reuser A.J.J.et al. Glycogenosis type II (acid maltase deficiency). Muscle Nerve. 3(Suppl.):1995;S61-S69.
3. Raben N.et al. Genetic defects in patients with glycogenosis type II (acid maltase deficiency). Muscle Nerve. 3:1995;570-574.
4. Martiniuk F.et al. Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am. J. Med. Genet. 79:1998;69-72.
5. Ausems M.G.et al. Frequency of glycogen storage disease type II in the Netherlands: implication for diagnosis and genetic counseling. Eur. J. Hum. Genet. 7:1999;713.
6. Hug G.et al. Treatment related observations in solid tissues, fibroblast cultures and amniotic fluid cells of type II glycogenosis, Hurler disease and metachromatic leukodystrophy. Birth Defects Org. Ser. 9:1967;160-183.
7. Slonim A.E.et al. Improvement of muscle function in acid maltase deficiency by high protein diet. Neurology. 33:1983;34.
8. de Barsy T.et al. Enzyme replacement in Pompe disease: an attempt with purified human acid α-glucosidase. Birth Defects Orig. Art. Ser. 9:1973;184-190.
9. Sabatini D., Adesnik M.B. The biogenesis of membranes and organelles. Scriver C.R.et al. The Metabolic and Molecular Basis of Inherited Disease. 1995;459-553 McGraw-Hill.
10. Kornfeld S. Structure and function of the mannose 6-phosphate/insulin-like growth factor II receptors. Annu. Rev. Biochem. 61:1992;307-330.
11. Tsuji A.et al. Intracellular transport of acid alpha-glucosidase in human fibroblasts: Evidence for involvement of phosphomannosyl receptor-independent system. J. Biochem. 104:1988;276-278.
12. Barton N.W.et al. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc. Natl. Acad. Sci. U. S. A. 87:1990;1913-1916.
13. Russell C.S., Clark L. Recombinant protein for genetic disease. Clin. Genet. 55:1999;389-390.
14. Brooks D.A. Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models. Mol. Genet. Metab. 68:1999;268-275.
15. Kakkis E.et al. Recombinant α-L-iduronidase replacement therapy in mucopolysaccharidosis I: results of a human clinical trial. Am. J. Hum. Genet. 63:1998;A25.
16. Schiffmann R.et al. Infusion of α-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc. Natl. Acad. Sci. U. S. A. 97:1999;365-370.
17. Roth K.S. Enzyme replacement therapy. Clin. Pediatr. 36:1997;147-148.
18. Van der Ploeg A.T.et al. Intravenous administration of phosphorylated acid alpha-glucosidase leads to uptake of enzyme in heart and skeletal muscle of mice. J. Clin. Invest. 87:1991;513-518.
19. Van Hove J.L.K.et al. High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease. Proc. Natl. Acad. Sci. U. S. A. 93:1996;65-70.
20. Fuller M.et al. Isolation and characterization of a recombinant precursor form of lysosomal acid alpha-glucosidase. Eur. J. Biochem. 234:1995;903-909.
21. Bijvoet A.G.A.et al. Recombinant human acid alpha-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice. Hum. Mol. Genet. 7:1998;1815-1824.
22. Bijvoet A.G.A.et al. Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease. Hum. Mol. Genet. 7:1998;53-62.
23. Raben N.et al. Targeted disruption of the acid alpha-glucosidase gene in mice cause an illness with critical features of both infantile and adult human glycogen storage disease type II. J. Biol. Chem. 273:1998;19086-19092.
24. Murakami H.et al. Glycogenosis II in a Japanese quail. Exp. Anim. 29:1980;475-485.
25. Kikuchi T.et al. Clinical and metabolic correction of Pompe disease by enzyme therapy in acid maltase deficient quail. J. Clin. Invest. 101:1998;827-833.
26. Bijvoet A.G.A.et al. Correction of enzyme deficiency and improved tissue morphology after long term enzyme replacement therapy in GSD-II knockout mice. Am. J. Hum. Genet. 63:1998;A397.
27. Bandyopadhyay P.et al. Nucleotide exchange in genomic DNA of rat hepatocytes using RNA/DNA oligonucleotides - Targeted delivery of liposomes and polyethyleneimine to the asialoglycoprotein receptor. J. Biol. Chem. 274:1999;10163-10172.
28. Zaretsky J.Z.et al. Retroviral transfer of acid alpha-glucosidase cDNA to enzyme-deficient myoblasts results in phenotypic spread of the genotypic correction by both secretion and fusion. Hum. Gene. Ther. 8:1997;1555-1563. [Hum. Gene Ther. (1998) 9(6):930 erratum].
29. Nicolino M.P.et al. Adenovirus-mediated transfer of the acid alpha-glucosidase gene into fibroblasts, myoblasts and myotubes from patients with glycogen storage disease type II leads to high level expression of enzyme and corrects glycogen accumulation. Hum. Mol. Genet. 7:1998;1695-1702.
30. Gussoni E.et al. The fate of individual myoblasts after transplantation into muscles of DMD patients. Nat. Med. 3:1997;970-977.
31. Wolff J.A.et al. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum. Mol. Genet. 1:1992;363-369.
32. Pauly D.F.et al. Complete correction of acid alpha-glucosidase deficiency in Pompe-disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle. Gene Ther. 5:1998;473-480.
33. Tsujino S.et al. Adenovirus-mediated transfer of human acid maltase gene reduces glycogen accumulation in skeletal muscle of Japanese quail with acid maltase deficiency. Hum. Gene Ther. 9:1998;1609-1616.
34. Greelish J.P.et al. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat. Med. 5:1999;439-443.
35. 2-adrenergic receptor gene delivery. J. Clin. Invest. 104:1999;21-29.
36. Hu H.M.et al. Persistence of an [E1-, polymerase-] adenovirus vector despite transduction of a neoantigen into immune-competent mice. Hum. Gene Ther. 10:1999;355-364.
37. Amalfitano A.et al. Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid α-glucosidase. Proc. Natl. Acad. Sci. U. S. A. 96:1999;8861-8866.
38. Ziegler R.J.et al. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer. Hum. Gene Ther. 10:1999;1667-1682.
39. Bittner R.G.et al. Recruitment of bone-marrow-derived cells by skeletal and cardiac muscle in adult dystrophic mdx mice. Anat. Embryol. 199:1999;391-396.
40. Ferrari G.et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science. 279:1998;1528-1530.
41. Gussoni E.et al. Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature. 401:1999;390-394.